269 related articles for article (PubMed ID: 34904809)
41. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in
Reiss KA; Mick R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Cowden S; Southwell T; Romeo J; Izgur N; Hannan ZM; Tondon R; Nathanson K; Vonderheide RH; Wattenberg MM; Beatty G; Domchek SM
J Clin Oncol; 2021 Aug; 39(22):2497-2505. PubMed ID: 33970687
[TBL] [Abstract][Full Text] [Related]
42. Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors.
Cheng X; Zhang B; Guo F; Wu H; Jin X
Mol Oncol; 2022 Apr; 16(7):1591-1607. PubMed ID: 34854226
[TBL] [Abstract][Full Text] [Related]
43. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
44. Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
Wang SP; Li Y; Huang SH; Wu SQ; Gao LL; Sun Q; Lin QW; Huang L; Meng LQ; Zou Y; Zhu QH; Xu YG
J Med Chem; 2021 Dec; 64(23):17413-17435. PubMed ID: 34813314
[TBL] [Abstract][Full Text] [Related]
45. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
Parsels LA; Engelke CG; Parsels J; Flanagan SA; Zhang Q; Tanska D; Wahl DR; Canman CE; Lawrence TS; Morgan MA
Mol Cancer Ther; 2021 Feb; 20(2):263-273. PubMed ID: 33268569
[TBL] [Abstract][Full Text] [Related]
46. [PARP Inhibitors: From the Mechanism of Action to Clinical Practice].
Branco C; Paredes J
Acta Med Port; 2022 Feb; 35(2):135-143. PubMed ID: 35225777
[TBL] [Abstract][Full Text] [Related]
47. Importance of
Martínez-Galán J; Rodriguez I; Caba O
World J Gastroenterol; 2021 Oct; 27(39):6515-6521. PubMed ID: 34754149
[TBL] [Abstract][Full Text] [Related]
48. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
49. What is the role of PARP inhibitors in pancreatic cancer?
Halder R; Shroff RT
Expert Rev Anticancer Ther; 2020 Nov; 20(11):913-918. PubMed ID: 32865047
[No Abstract] [Full Text] [Related]
50. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
51. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
52. BRCA mutations in pancreatic cancer and progress in their targeting.
Alkassis S; Yazdanpanah O; Philip PA
Expert Opin Ther Targets; 2021 Jul; 25(7):547-557. PubMed ID: 34289788
[No Abstract] [Full Text] [Related]
53. Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer.
Cilento MA; Poplawski NK; Paramasivam S; Thomas DM; Kichenadasse G
J Natl Compr Canc Netw; 2021 Nov; 19(11):1212-1217. PubMed ID: 34781271
[TBL] [Abstract][Full Text] [Related]
54. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
Fogelman DR; Wolff RA; Kopetz S; Javle M; Bradley C; Mok I; Cabanillas F; Abbruzzese JL
Anticancer Res; 2011 Apr; 31(4):1417-20. PubMed ID: 21508395
[TBL] [Abstract][Full Text] [Related]
55. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
56. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
57. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
[TBL] [Abstract][Full Text] [Related]
58. Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases.
Martínez-Bosch N; Fernández-Zapico ME; Navarro P; Yélamos J
Am J Pathol; 2016 Feb; 186(2):234-41. PubMed ID: 26687988
[TBL] [Abstract][Full Text] [Related]
59. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
[TBL] [Abstract][Full Text] [Related]
60. Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials.
Zhang Z; Song J; Xie C; Pan J; Lu W; Liu M
AAPS J; 2021 Feb; 23(2):29. PubMed ID: 33580411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
